Jeffrey E Kropf

USPTO Granted Patents = 45 (Patent Applications = 14)

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 23 (Patent Applications = 23)

Average Co-Inventor Count = 9.6

ph-index = 14

Forward Citations = 395(Granted Patents)

Location History:

Branford, CT (US) (2010 - 2019)
Issaquah, WA (US) (2017 - 2024)

Company Filing History:

21 out of 919

Gilead Sciences, Inc.

patents

16 out of 30

Gilead Connecticut, Inc.

Cgi Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

45 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358903 - FXR (NR1H4) modulating compounds (2025-07-15),

2. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

3. 12053462 - Quinoline derivatives (2024-08-06),

4. 11739065 - FXR (NR1H4) modulating compounds (2023-08-29),

5. 11578069 - Compounds for inhibition of α4 β7 integrin (2023-02-14),

6. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

7. 11247986 - FXR (NR1H4) modulating compounds (2022-02-15),

8. 11225473 - FXR (NR1H4) modulating compounds (2022-01-18),

9. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

10. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

11. 11174256 - Imidazopyridine derivatives (2021-11-16),

12. 11116760 - Quinoline derivatives (2021-09-14),

13. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

14. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

15. 10774054 - FXR (NR1H4) modulating compounds (2020-09-15),

Title: Jeffrey E Kropf: Pioneering Innovations in Pharmaceutical Compounds

Introduction:

Jeffrey E Kropf, a prolific inventor based in Issaquah, WA, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 42 patents, Kropf is known for his groundbreaking work in developing compounds for the treatment of various diseases.

Latest Patents:

Kropf's latest patents showcase his expertise in developing cutting-edge pharmaceutical compounds. One of his recent patents involves FXR (NR1H4) modulating compounds, which act as agonists of the FXR receptor. These compounds show promise in treating a range of diseases by binding to the nuclear receptor. Another notable patent pertains to compounds for the inhibition of α4 β7 integrin, offering innovative solutions for treating inflammatory diseases.

Career Highlights:

Throughout his career, Kropf has worked with leading companies in the pharmaceutical industry. Some of the notable companies he has been associated with include Gilead Sciences, Inc. and Gilead Connecticut, Inc. His tenure at these companies has been marked by groundbreaking research and innovative discoveries that have shaped the field of pharmaceuticals.

Collaborations:

Kropf's collaborative efforts with esteemed colleagues, such as Kevin S Currie and Peter A Blomgren, have been instrumental in advancing pharmaceutical research. Together, they have worked on developing novel compounds and therapeutic methods that hold promise in revolutionizing the treatment of various diseases.

Conclusion:

Jeffrey E Kropf's pioneering work in the development of pharmaceutical compounds underscores his dedication to innovation and scientific advancement. With a diverse portfolio of patents and a successful track record in the industry, Kropf continues to make significant contributions to the field of pharmaceutical research, ultimately aiming to improve healthcare outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.